Enzalutamide (CAS 915087-33-1) is a high-purity androgen receptor inhibitor API, specially designed for targeted treatment of prostate cancer. With a precise molecular structure, it selectively binds to androgen receptors, blocking androgen signaling pathways and effectively inhibiting the proliferation and survival of hormone-dependent prostate cancer cells.
Produced under strict GMP standards, this API ensures consistent purity (≥99%), potency, and stability, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for castration-resistant prostate cancer (CRPC) and metastatic prostate cancer treatment, catering to the needs of pharmaceutical manufacturers and research institutions focusing on antitumor pharmaceutical R&D.
Its specific androgen receptor inhibition mechanism ensures targeted efficacy while reducing systemic toxicity, achieving a favorable balance between therapeutic effect and safety. As a core raw material for prostate cancer targeted therapy, Enzalutamide delivers reliable performance for both preclinical research and large-scale pharmaceutical production, supporting the development of effective treatments for advanced prostate cancer.
